Medical resource use and costs among rheumatoid arthritis patients receiving disease-modifying antirheumatic drug therapy.

OBJECTIVE To identify costs among rheumatoid arthritis (RA) patients receiving alternative disease-modifying antirheumatic drug (DMARD) therapies. METHODS Using managed care organization data, we identified members who (a) were prescribed any DMARD therapy for two consecutive months between July 1993 and February 1998, (b) were aged > or = 18 years, (c) had > or = 6 months of DMARD-free enrollment prior to the first DMARD, and (d) had a diagnosis of RA. RESULTS The average age of the cohort (n = 571) was 51 years, and 70% were women. Mean duration of enrollment following initiation of DMARD therapy (observation period) was 19.5 months; 28.8% of patients switched DMARD regimens. The average monthly cost of care was $853, of which $294 (34%) was for RA-coded medical services. Monthly RA-coded costs varied by DMARD: hydroxychloroquine $227 (n = 252), methotrexate $340 (n = 185); sulfasalazine $233 (n = 49), and other mono/combination therapy $425 (n = 85) (P = 0.001). CONCLUSION Costs of RA-coded care in patients receiving DMARDs are low and vary by DMARD.

[1]  J. Block,et al.  The Prosorba column for treatment of refractory rheumatoid arthritis: a randomized, double-blind, sham-controlled trial. , 1999, Arthritis and rheumatism.

[2]  J. Kremer,et al.  Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. , 1999, Arthritis and rheumatism.

[3]  E. Yelin,et al.  An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. , 1999, Arthritis and rheumatism.

[4]  L. Callahan.  The burden of rheumatoid arthritis: facts and figures. , 1998, The Journal of rheumatology. Supplement.

[5]  B. Rozman.  Clinical experience with leflunomide in rheumatoid arthritis. Leflunomide Investigators' Group. , 1998, The Journal of rheumatology. Supplement.

[6]  C. Helmick,et al.  Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. , 1998, Arthritis and rheumatism.

[7]  M. Liang,et al.  Sensitivity and positive predictive value of Medicare Part B physician claims for rheumatologic diagnoses and procedures. , 1997, Arthritis and rheumatism.

[8]  C. Bombardier,et al.  A summary of economic evaluations published in the field of rheumatology and related disciplines. , 1997, Arthritis and rheumatism.

[9]  N. Dreyer,et al.  Resource utilization and cost of care for rheumatoid arthritis and osteoarthritis in a managed care setting: the importance of drug and surgery costs. , 1997, Arthritis and rheumatism.

[10]  E. Tindall,et al.  Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. , 1997, The New England journal of medicine.

[11]  L. Criswell,et al.  Health care utilization and outcomes among persons with rheumatoid arthritis in fee-for-service and prepaid group practice settings. , 1996, JAMA.

[12]  J. Forder,et al.  A comparison of the cost-effectiveness of sertraline versus tricyclic antidepressants in primary care. , 1996, Journal of affective disorders.

[13]  C. Kwoh,et al.  Guidelines for the management of rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. , 1996, Arthritis and rheumatism.

[14]  E. Yelin.  The costs of rheumatoid arthritis: absolute, incremental, and marginal estimates. , 1996, The Journal of rheumatology. Supplement.

[15]  D. Lubeck,et al.  The economic impact of arthritis. , 1995, Arthritis care and research : the official journal of the Arthritis Health Professions Association.

[16]  K. Aho,et al.  Mortality in rheumatoid arthritis. , 1995, Seminars in arthritis and rheumatism.

[17]  G S Alarcón,et al.  Epidemiology of rheumatoid arthritis. , 1995, Rheumatic diseases clinics of North America.

[18]  R. Meenan,et al.  The total costs of drug therapy for rheumatoid arthritis. A model based on costs of drug, monitoring, and toxicity. , 1995, Arthritis and rheumatism.

[19]  F. Wolfe,et al.  The mortality of rheumatoid arthritis. , 1994, Arthritis and rheumatism.

[20]  S. Gabriel.  The sensitivity and specificity of computerized databases for the diagnosis of rheumatoid arthritis. , 1994, Arthritis and rheumatism.

[21]  Wiesenhutter Cw,et al.  Treatment of patients with refractory rheumatoid arthritis with extracorporeal protein A immunoadsorption columns: a pilot trial. , 1994 .

[22]  S. Pillemer,et al.  Rheumatoid arthritis and mortality. A longitudinal study in Pima Indians. , 1993, Arthritis and rheumatism.

[23]  J J Anderson,et al.  The American college of rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials , 1993 .

[24]  F. Epstein,et al.  Rheumatoid arthritis. Pathophysiology and implications for therapy. , 1990, The New England journal of medicine.

[25]  D. Lubeck,et al.  The impact of rheumatoid arthritis and osteoarthritis: the activities of patients with rheumatoid arthritis and osteoarthritis compared to controls. , 1987, The Journal of rheumatology.

[26]  E. Yelin,et al.  The work dynamics of the person with rheumatoid arthritis. , 1987, Arthritis and rheumatism.

[27]  M. Nevitt,et al.  Risk factors for hospitalization and surgery in patients with rheumatoid arthritis: implications for capitated medical payment. , 1986, Annals of internal medicine.

[28]  D. Lubeck,et al.  A multicenter study of hospitalization in rheumatoid arthritis. Frequency, medical-surgical admissions, and charges. , 1986, Arthritis and rheumatism.

[29]  D. Lubeck,et al.  A multicenter study of annual health service utilization and costs in rheumatoid arthritis. , 1986, Arthritis and rheumatism.

[30]  E. Yelin,et al.  Health Outcomes for a Chronic Disease in Prepaid Group Practice and Fee for Service Settings: The Case of Rheumatoid Arthritis , 1986, Medical care.

[31]  M. Nevitt,et al.  A comparison of the treatment of rheumatoid arthritis in health maintenance organizations and fee-for-service practices. , 1985, The New England journal of medicine.

[32]  F. C. Mcduffie,et al.  Morbidity impact of rheumatoid arthritis on society. , 1985, The American journal of medicine.

[33]  Stone Ce.  The lifetime economic costs of rheumatoid arthritis. , 1984 .

[34]  D. L. Curtis,et al.  The costs of rheumatoid arthritis. A patient-oriented study of chronic disease costs. , 1978, Arthritis and rheumatism.

[35]  B. Rozman.  Clinical experience with leflunomide in rheumatoid arthritis , 1998 .

[36]  S. Gabriel,et al.  Indirect and nonmedical costs among people with rheumatoid arthritis and osteoarthritis compared with nonarthritic controls. , 1997, The Journal of rheumatology.

[37]  T. Spector,et al.  Epidemiology of rheumatoid arthritis: update. , 1990, Epidemiologic reviews.

[38]  H. C. Hutchings,et al.  The total cost of care and the use of pharmaceuticals in the management of rheumatoid arthritis: the Medi-Cal program. , 1988, Journal of clinical epidemiology.